It is not intended for human consumption, medical use, or therapeutic application.
MK-677 is metabolized primarily by CYP3A4 in the liver, and its metabolites are excreted renally
Weeks 1-4: Initiation Phase During the first month, Retatrutide effects dominate
While chest pain is not a common side effect listed in FDA prescribing information, patients may experience chest discomfort through various mechanisms including gastrointestinal effects, reflux, or unrelated cardiac conditions
The fixed 5:1 ratio means you cannot start low on one compound while ramping the other - if you raise retatrutide, cagrilintide goes up proportionally
The bottom line: With a healthy diet and regular exercise, GLP-1 medication can led to significant weight loss